These Analysts See Upside At Continental Resources
In a report published Thursday, Wedbush Morgan analyst David Nierengarten maintained an Outperform rating on bluebird bio, Inc (NASDAQ: BLUE), with a price target of $146.
In the report, Wedbush Morgan noted, "BLUE reported a 4Q net loss of $19.5M ($0.67), below our estimate and consensus ($0.58). The company is well financed, with $492M in cash on hand at YE14, sufficient in management's view to fund operations through 2017."
"Based on positive preliminary data presented at ASH, we expect the first SCD patient from the French HGB-205 study of LentiGlobin to achieve transfusion-independence in H1:15…Positive results would provide the first example of SCD being successfully treated with gene therapy. Given the greater prevalence (especially in the US) and awareness of SCD over beta-thal, the data should drive even greater levels of investor interest in BLUE," Nierengarten wrote.
"We expect the LentiGlobin Ph 1/2 studies Northstar in beta-thal (n=15) and HGB-205 in beta-thal and SCD (n=7) to complete enrollment this year, along with the Ph 2/3 Starbeam study of Lenti-D in CCALD (n=15). We expect enrollment in Starbeam, which has thus far been conducted in the US, to be expanded into Europe this year," the analyst added.
Latest Ratings for CLR
|Jan 2017||KLR Group||Upgrades||Hold||Buy|
|Dec 2016||FBR Capital||Initiates Coverage On||Market Perform|
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.